Stop VTE Prophylaxis at Discharge for Most COVID-19 Patients

February 2022

New data will spark debate about the role of postdischarge venous thromboembolism (VTE) prophylaxis in COVID-19 patients.

We know that COVID-19 patients should receive VTE prophylaxis while hospitalized...which typically stops at discharge.

Now data suggest rivaroxaban (Xarelto) 10 mg daily for 35 days postdischarge in COVID-19 patients with HIGH clotting and LOW bleeding risk reduces VTE...without increasing bleeding.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote